European HIV Clinical Forum 2017

Slideset

HIV

State of the ART: Integrase Inhibitors Resistance- Charles Boucher, MD, PhD

Slideset

HIV

What is the virological support for reduced drug regimens?- Anne-Geneviève Marcelin, MD

Slideset

HIV

What is the clinical support for reduced drug regimens?- David Cooper, MD, DSc

Slideset

HIV

Real Life Experience of Dolutegravir and Lamivudine Dual Therapy as a Switching Regimen in HIV-TR Cohort.- D. Yağcı-Çağlayık

Slideset

HIV

Dolutegravir used in real-life provides high rates of virological response in conjunction with a rare emergence of integrase resistance.- D. Armenia

Slideset

HIV

French national survey of resistance to integrase inhibitors in a context of routine hospital care (ANRS AC11 Virology Network).- A.G. Marcelin

Slideset

HIV

Clinical case presentation- Christina Mussini, MD

Slideset

HIV

In-vitro selection of resistance mutations to dolutegravir outside HIV-1 integrase.- Dr. Olivier Delelis

Slideset

HIV

Genetic variability of HIV-2 LTR regions impacts transcriptional activities.- Q. Le Hingrat

Slideset

HIV

Serum cystatine as a marker for estimated glomerular filtration rate (eGFR) assessment in HIV-1-infected patients with dolutegravir-based antiretroviral therapy (ART).- R. Palich

Slideset

HIV

Clinical case presentation- Miłosz Parczewski, MD, PhD

Slideset

HIV

Evolution of bone mineral density and MDRD in HIV-infected patients treated with dolutegravir based regimens: results at 48- weeks- A. D'Avino

Slideset

HIV

Prospects of immunotherapy for treatment- Michael Lederman, MD

Slideset

HIV

European HIV Clinical Forum 2017

State of the ART: Integrase Inhibitors Resistance- Charles Boucher, MD, PhD

What is the virological support for reduced drug regimens?- Anne-Geneviève Marcelin, MD

What is the clinical support for reduced drug regimens?- David Cooper, MD, DSc

Real Life Experience of Dolutegravir and Lamivudine Dual Therapy as a Switching Regimen in HIV-TR Cohort.- D. Yağcı-Çağlayık

Dolutegravir used in real-life provides high rates of virological response in conjunction with a rare emergence of integrase resistance.- D. Armenia

French national survey of resistance to integrase inhibitors in a context of routine hospital care (ANRS AC11 Virology Network).- A.G. Marcelin

Clinical case presentation- Christina Mussini, MD

In-vitro selection of resistance mutations to dolutegravir outside HIV-1 integrase.- Dr. Olivier Delelis

Genetic variability of HIV-2 LTR regions impacts transcriptional activities.- Q. Le Hingrat

Serum cystatine as a marker for estimated glomerular filtration rate (eGFR) assessment in HIV-1-infected patients with dolutegravir-based antiretroviral therapy (ART).- R. Palich

Clinical case presentation- Miłosz Parczewski, MD, PhD

Evolution of bone mineral density and MDRD in HIV-infected patients treated with dolutegravir based regimens: results at 48- weeks- A. D'Avino

Prospects of immunotherapy for treatment- Michael Lederman, MD

One pill a day?: Integration novel delivery systems into routine care- Giovanni Di Perri, MD, PhD